Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Targeted Combo Topples Chemo in Pediatric Glioma With BRAF Mutations
(MedPage Today) -- CHICAGO -- Dual targeted therapy with a BRAF and MEK inhibitor quadrupled responses in pediatric BRAF-mutant low-grade glioma and reduced risk of disease progression or death compared with standard chemotherapy, a phase II... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news
Targeted Therapy an'Important Advance' in Childhood Glioma Targeted Therapy an'Important Advance' in Childhood Glioma
Combining dabrafenib with trametinib markedly improved response rates and delayed progression over standard-of-care chemotherapy in pediatric BRAF V600-mutant low-grade glioma in a phase 2 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 6, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Imaging Biometrics seeks FDA clearance for IB Zero G
Advanced visualization software developer Imaging Biometrics has submitted ...Read more on AuntMinnie.comRelated Reading:
Imaging Biometrics highlights findings on MRI-based glioma monitoring
Imaging Biometrics lands software install at Ala. medical center
Imaging Biometrics secures patent for zero-dose imaging software
Imaging Biometrics wins USC installation
Imaging Biometrics added to Arterys marketplace (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 31, 2022 Category: Radiology Source Type: news
The Potential of Nanopore Sequencing Technology in Cancer Diagnosis
In this webinar, Mashiat Mimosa will discuss the potential of a new sequencing method that detects glioma tumors in brain tissue. (Source: The Scientist)
Source: The Scientist - May 11, 2022 Category: Science Tags: Sponsored Webinars Source Type: news
Blood Biomarkers May Help ID Primary CNS Lymphoma, High - Grade Glioma
Systemic inflammatory biomarkers may be useful in the differential diagnosis of primary central nervous system lymphoma, high - grade glioma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 18, 2022 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Journal, Source Type: news
Blood Biomarkers May Help ID Primary CNS Lymphoma, High-Grade Glioma
MONDAY, April 18, 2022 -- Systemic inflammatory biomarkers may aid in differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG), according to a study published online April 4 in CNS Oncology.
Tejpal Gupta, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 18, 2022 Category: Pharmaceuticals Source Type: news
Assay-Guided Chemo in Recurrent Glioma Linked to Longer Survival Assay-Guided Chemo in Recurrent Glioma Linked to Longer Survival
A new assay can help guide chemotherapy treatments for recurrent high-grade gliomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 18, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Imaging Biometrics highlights findings on MRI-based glioma monitoring
Advanced visualization software firm Imaging Biometrics is highlighting researc...Read more on AuntMinnie.comRelated Reading:
Imaging Biometrics lands software install at Ala. medical center
Imaging Biometrics secures patent for zero-dose imaging software
IB, Mayo Clinic partner to track brain lesions
Imaging Biometrics wins USC installation
Imaging Biometrics added to Arterys marketplace (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 7, 2022 Category: Radiology Source Type: news
What Is the Survival Rate of Glioma?
Title: What Is the Survival Rate of Glioma?Category: Diseases and ConditionsCreated: 2/16/2022 12:00:00 AMLast Editorial Review: 2/16/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2022 Category: Cancer & Oncology Source Type: news
Targeted drug combination shows unprecedented activity in some highly aggressive brain tumors
A combination of two targeted cancer drugs showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
The drug combination, which blocked an overactive cell-growth signaling pathway, shrank tumors by 50% or more in one-third of 45 patients with hard-to-treat high-grade gliomas, including glioblastomas, the most aggressive brain tumor. (Source: World Pharma News)
Source: World Pharma News - November 25, 2021 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment
Funds to support first-in-human (FIH) clinical trial of the company's proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas
OAKDALE, Minn., Nov. 17, 2021 -- (Healthcare Sales & Marketing Network) -- Alpheus ... Devices, Oncology, Venture Capital Alpheus Medical, sonodynamic therapy, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 17, 2021 Category: Pharmaceuticals Source Type: news
Dual-drug treatment offers hope to children with rare brain cancer
Scientists make ‘promising’ breakthrough on fast-growing DIPG type of tumourScientists have successfully combined two existing cancer drugs to create a treatment for children diagnosed with deadly brain tumours.Diffuse intrinsic pontine glioma (DIPG), a rare and fast-growing type of brain tumour in children, can mutate and evolve to resist treatment with a single drug. There is currently no cure and many children found to have the disease die within months.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - November 5, 2021 Category: Science Authors: Andrew Gregory Health editor Tags: Medical research Cancer Children's health UK news Science Source Type: news
Novel Virus Targeting Deadly Brain Tumors Shows Early Promise Novel Virus Targeting Deadly Brain Tumors Shows Early Promise
Early evidence suggests that an oncolytic virus engineered to kill malignant gliomas may improve survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Upstate Foundation awards $50,000 for brain cancer research
Funding supports research program to develop novel treatments for patients with malignant gliomas, the most aggressive form of brain cancer (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - September 1, 2021 Category: Universities & Medical Training Tags: News Source Type: news
